Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Danaher to acquire Aldevron for $9.6B

By Sean Whooley | June 22, 2021

danaher AldevronDanaher (NYSE:DHR) announced that it entered into a definitive agreement to acquire Aldevron for approximately $9.6 billion.

Fargo, N.D.-based Aldevron, which employs approximately 600 people, manufactures high-quality plasmid DNA, mRNA and proteins to serve biotechnology and pharmaceutical customers across research, clinical and commercial applications.

According to a news release, Aldevron will operate as a standalone operating company and brand within Danaher’s life sciences business segment.

“We are thrilled to have Aldevron join Danaher’s life sciences segment. For nearly 25 years, Aldevron has made tremendous contributions to the advancement of cell, gene and other novel therapies and vaccines,” Danaher president & CEO Rainer M. Blair said in the release. This acquisition will expand our capabilities into the important field of genomic medicine and help us support our customers and their critical mission to bring more life-saving therapies and vaccines to market faster.”

Danaher expects to finance the $9.6 billion acquisition using cash on hand and/or proceeds from the issuance of commercial paper. The transaction is subject to customary conditions, including the receipt of applicable regulatory approvals.

“Joining Danaher will help us expand our global reach and harness the power of the Danaher business system to continue supporting our customers with best-in-class products and services,” Aldevron founder & executive chairman Michael Chambers said. “I’m incredibly excited for Aldevron to take this pivotal next step with Danaher and look forward to the tremendous impact we can make together in the expanding area of genomic medicine.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

GSK
GSK finalizes Affinivax acquisition 
vaccine
U.S. government makes an additional 442,000 monkeypox vaccine doses available 
Biogen logo
Biogen is scaling back space outside Boston
Fresenius Kabi
Fresenius Kabi plans to add 2D barcodes to its pharmaceutical portfolio

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards